AnaptysBio (MEX:ANAB) Cyclically Adjusted Revenue per Share: MXN34.57 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ANAB AnaptysBio Inc MEX:ANAB
67 GF Score
Price MXN445.25
GF Value MXN458.99
! 2 Warning Signs
View Full Analysis

What is AnaptysBio Cyclically Adjusted Revenue per Share?

AnaptysBio MEX:ANAB 67 Cyclically Adjusted Revenue per Share is MXN34.57 as of Mar. 2026. GuruFocus rates MEX:ANAB with a GF Score™ of 67/100 and a GF Value™ of MXN458.99. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

AnaptysBio's adjusted revenue per share for the three months ended in Mar. 2026 was MXN16.062. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN34.57 for the trailing ten years ended in Mar. 2026.

During the past 12 months, AnaptysBio's average Cyclically Adjusted Revenue Growth Rate was 51.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-18), AnaptysBio's current stock price is MXN445.25081. AnaptysBio's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN34.57. AnaptysBio's Cyclically Adjusted PS Ratio of today is 12.88.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AnaptysBio was 24.16. The lowest was 5.33. And the median was 10.60.


AnaptysBio  (MEX:ANAB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AnaptysBio's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=445.25081/34.57
=12.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AnaptysBio was 24.16. The lowest was 5.33. And the median was 10.60.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


AnaptysBio Cyclically Adjusted Revenue per Share Related Terms


AnaptysBio Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for AnaptysBio's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AnaptysBio Cyclically Adjusted Revenue per Share Chart

AnaptysBio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 77.53 38.03

AnaptysBio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.28 52.51 43.75 38.03 34.57

MEX:ANAB vs ABSI, TSHA, RXRX: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, AnaptysBio's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AnaptysBio Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AnaptysBio's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AnaptysBio's Cyclically Adjusted PS Ratio falls into.


MEX:ANAB
67GF Score
AnaptysBio Inc MEX:ANAB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AnaptysBio Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AnaptysBio's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=16.062/330.2130*330.2130
=16.062

Current CPI (Mar. 2026) = 330.2130.

AnaptysBio Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 7.218 241.018 9.889
201609 4.146 241.428 5.671
201612 3.127 241.432 4.277
201703 0.000 243.801 0.000
201706 6.242 244.955 8.415
201709 0.000 246.819 0.000
201712 2.548 246.524 3.413
201803 0.000 249.554 0.000
201806 0.000 251.989 0.000
201809 3.873 252.439 5.066
201812 0.000 251.233 0.000
201903 0.000 254.202 0.000
201906 3.554 256.143 4.582
201909 0.000 256.759 0.000
201912 2.082 256.974 2.675
202003 12.901 258.115 16.505
202006 0.000 257.797 0.000
202009 0.000 260.280 0.000
202012 43.639 260.474 55.323
202103 8.402 264.877 10.474
202106 21.822 271.696 26.522
202109 15.656 274.310 18.847
202112 0.753 278.802 0.892
202203 0.697 287.504 0.801
202206 0.867 296.311 0.966
202209 0.919 296.808 1.022
202212 4.666 296.797 5.191
202303 0.886 301.836 0.969
202306 2.228 305.109 2.411
202309 2.177 307.789 2.336
202312 5.750 306.746 6.190
202403 4.446 312.332 4.701
202406 7.347 314.175 7.722
202409 20.456 315.301 21.423
202412 29.515 315.605 30.881
202503 18.540 319.799 19.144
202506 14.550 322.561 14.895
202509 48.247 324.800 49.051
202512 70.170 324.054 71.504
202603 16.062 330.213 16.062

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN34.57 mean?
AnaptysBio (MEX:ANAB) has a Cyclically Adjusted Revenue per Share of MXN34.57 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AnaptysBio and its competitors.
Is AnaptysBio's Cyclically Adjusted Revenue per Share too high?
AnaptysBio's current Cyclically Adjusted Revenue per Share is MXN34.57. Overall, AnaptysBio has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does AnaptysBio's Cyclically Adjusted Revenue per Share compare to ABSI and TSHA?
AnaptysBio's Cyclically Adjusted Revenue per Share of MXN34.57 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AnaptysBio and its competitors. AnaptysBio's current Cyclically Adjusted Revenue per Share is MXN34.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AnaptysBio stock overvalued right now?
AnaptysBio (MEX:ANAB) has a current Cyclically Adjusted Revenue per Share of MXN34.57. The stock's GF Value™ is MXN458.99, compared to a current price of MXN445.25 — trading 3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN34.57. AnaptysBio's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For AnaptysBio (MEX:ANAB), the current Cyclically Adjusted Revenue per Share is MXN34.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AnaptysBio (MEX:ANAB) Overvalued in 2026?

Based on GuruFocus' analysis, AnaptysBio stock appears to be undervalued. The current stock price of MXN445.25 is trading 3% below its estimated GF Value™ of MXN458.99.

Key valuation signals for MEX:ANAB:

  • Cyclically Adjusted Revenue per Share: MXN34.57
  • GF Value™: MXN458.99 vs. price of MXN445.25 (3% below fair value)
  • GF Score™: 67/100 with 2 warning signs

No single metric tells the full story. See the MEX:ANAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AnaptysBio Business Description

Other Exchanges ANAB:USA0HFQ:UKAN6:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
67GF Score

Get the complete analysis for MEX:ANAB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN445.25
Price
MXN458.99
GF Value